Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC

NACompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

February 28, 2019

Study Completion Date

August 31, 2020

Conditions
Esophageal Squamous Cell Carcinoma Stage cT3-4aN0-1M0
Interventions
PROCEDURE

Neoadjuvant Chemoradiotherapy

Before surgery, patients in this group receive neoadjuvant chemoradiotherapy. A total dose of 40 Gy is delivered in 20 fractions (5 fractions per week) for 4 weeks. Chemotherapy is delivered concomitantly and composed of four cycles of paclitaxel 50mg per square meter of body-surface area and cisplatin 25mg per square meter of body-surface area weekly at the intervals of radiotherapy. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.

PROCEDURE

Neoadjuvant Chemotherapy

Before surgery, patients in this group receive neoadjuvant chemotherapy. Chemotherapy is delivered and composed of two cycles of paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 4 weeks. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.

PROCEDURE

Minimally Invasive Esophagectomy

After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy

Trial Locations (1)

200032

Shanghai Zhongshan Hospital, Shanghai

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Fujian Medical University Union Hospital

OTHER

collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

Shanghai Chest Hospital

OTHER

collaborator

First Affiliated Hospital of Chongqing Medical University

OTHER

collaborator

Changzhi Medical College

OTHER

collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

collaborator

Peking University Cancer Hospital and Institute

OTHER

lead

Shanghai Zhongshan Hospital

OTHER